Louis Zizhao Wang1,2, Carol Y Cheung1,3, Robyn J Tapp1,4,5, Haslina Hamzah1, Gavin Tan1, Daniel Ting1, Ecosse Lamoureux1,6, Tien Yin Wong1,6. 1. Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore. 2. Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 3. Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong. 4. Department of Optometry and Vision Sciences, The University of Melbourne, Melbourne, Victoria, Australia. 5. School of Clinical and Applied Sciences, Leeds Beckett University, Leeds, UK. 6. Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
Abstract
BACKGROUND: Diabetic retinopathy (DR) is a blinding yet treatable complication of diabetes. DR screening is highly cost-effective at reducing blindness. Amidst the rapidly growing diabetic population in Asia, the prevalence of DR in the region is relatively less well known. AIMS: To review existing national DR screening guidelines of 50 countries in Asia, compare them against the International Council of Ophthalmology (ICO) guideline, and summarise the prevalence rates of DR and sight-threatening DR (STDR) in these countries. METHODS: We systematically searched for published guidelines from the National Guideline Clearinghouse and other databases, and contacted local diabetic and ophthalmological associations of all 50 Asian countries. RESULTS: Eleven Asian countries have published relevant guidelines, nine of which pertain to general diabetes care and two are DR-specific, covering less than half of Asia's population. The median DR prevalence among patients with diabetes is 30.5% (IQR: 23.2%-36.8%), similar to the USA and the UK. However, rates of STDR are consistently higher. All guidelines from the 11 Asian countries fulfil the ICO standard on when to start and repeat screening, except for screening interval for pregnant patients. However, only 2 of the 11 guidelines fulfil the ICO referral criteria and 6 partially fulfil. A third of the recommendations on screening process, equipment and personnel is either unavailable or incomplete. CONCLUSIONS: Countries in Asia need to establish more comprehensive and evidence-based DR screening guidelines to facilitate the execution of robust screening programmes that could help reduce DR-related blindness, improve patient outcomes and reduce healthcare costs. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
BACKGROUND:Diabetic retinopathy (DR) is a blinding yet treatable complication of diabetes. DR screening is highly cost-effective at reducing blindness. Amidst the rapidly growing diabetic population in Asia, the prevalence of DR in the region is relatively less well known. AIMS: To review existing national DR screening guidelines of 50 countries in Asia, compare them against the International Council of Ophthalmology (ICO) guideline, and summarise the prevalence rates of DR and sight-threatening DR (STDR) in these countries. METHODS: We systematically searched for published guidelines from the National Guideline Clearinghouse and other databases, and contacted local diabetic and ophthalmological associations of all 50 Asian countries. RESULTS: Eleven Asian countries have published relevant guidelines, nine of which pertain to general diabetes care and two are DR-specific, covering less than half of Asia's population. The median DR prevalence among patients with diabetes is 30.5% (IQR: 23.2%-36.8%), similar to the USA and the UK. However, rates of STDR are consistently higher. All guidelines from the 11 Asian countries fulfil the ICO standard on when to start and repeat screening, except for screening interval for pregnant patients. However, only 2 of the 11 guidelines fulfil the ICO referral criteria and 6 partially fulfil. A third of the recommendations on screening process, equipment and personnel is either unavailable or incomplete. CONCLUSIONS: Countries in Asia need to establish more comprehensive and evidence-based DR screening guidelines to facilitate the execution of robust screening programmes that could help reduce DR-related blindness, improve patient outcomes and reduce healthcare costs. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Daniel Shu Wei Ting; Carol Yim-Lui Cheung; Gilbert Lim; Gavin Siew Wei Tan; Nguyen D Quang; Alfred Gan; Haslina Hamzah; Renata Garcia-Franco; Ian Yew San Yeo; Shu Yen Lee; Edmund Yick Mun Wong; Charumathi Sabanayagam; Mani Baskaran; Farah Ibrahim; Ngiap Chuan Tan; Eric A Finkelstein; Ecosse L Lamoureux; Ian Y Wong; Neil M Bressler; Sobha Sivaprasad; Rohit Varma; Jost B Jonas; Ming Guang He; Ching-Yu Cheng; Gemmy Chui Ming Cheung; Tin Aung; Wynne Hsu; Mong Li Lee; Tien Yin Wong Journal: JAMA Date: 2017-12-12 Impact factor: 56.272
Authors: Fangyao Tang; Xi Wang; An-Ran Ran; Carmen K M Chan; Mary Ho; Wilson Yip; Alvin L Young; Jerry Lok; Simon Szeto; Jason Chan; Fanny Yip; Raymond Wong; Ziqi Tang; Dawei Yang; Danny S Ng; Li Jia Chen; Marten Brelén; Victor Chu; Kenneth Li; Tracy H T Lai; Gavin S Tan; Daniel S W Ting; Haifan Huang; Haoyu Chen; Jacey Hongjie Ma; Shibo Tang; Theodore Leng; Schahrouz Kakavand; Suria S Mannil; Robert T Chang; Gerald Liew; Bamini Gopinath; Timothy Y Y Lai; Chi Pui Pang; Peter H Scanlon; Tien Yin Wong; Clement C Tham; Hao Chen; Pheng-Ann Heng; Carol Y Cheung Journal: Diabetes Care Date: 2021-07-27 Impact factor: 17.152